Director/PDMR Shareholding

RNS Number : 2532W

SkinBioTherapeutics PLC

16 April 2019

 

SkinBioTherapeutics plc

Director Dealing

Manchester, UK - 16 April 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, announces it was notified on 15 April 2019, that Dr Cathy Prescott, a Non-Executive Director of the Company, acquired 56,112 ordinary shares on 15 April 2019 at a price of 17.82p per share.

Dr Prescott now holds 56,112 ordinary shares in the Company, representing 0.04% of the Company's issued share capital.

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For more information please contact:

SkinBioTherapeutics plc Dr Cath O'Neill, CEO Doug Quinn, CFO	Tel: [phone]
Cairn Financial Advisers LLP (Nominated Adviser) Tony Rawlinson / Sandy Jamieson / Richard Nash	Tel: [phone]
Turner Pope Investments (Joint Broker) Ben Turner / James Pope SP Angel Corporate Finance (Joint Broker) Vadim Alexandre / Abigail Wayne	Tel: [phone] Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Deborah Bell	Tel: [phone] [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017, concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr Cathy Prescott
2	Reason for notification	Acquisition of shares
a.	Position/Status	Non-Executive Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics Plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each   ISIN: GB00BF33H870
b.	Nature of the transaction	Share purchase
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			17.82p	56,112
d.	Aggregated information - Aggregated Volume - Price	56,112 17.82p
e.	Date of the transaction	15th April 2019
f.	Place of the transaction	London Stock Exchange

 

END

 

 

DSHEELFFKZFXBBV